CASE STUDY: See how Poseida Therapeutics is utilizing the “dual benefits” of our Nanoplasmid™ vector for success

Data from their ongoing Phase 1 expansion trial using Nanoplasmid demonstrated an improvement in efficacy over standard plasmid and a potentially best-in-class safety profile.